You are hereJuly 5, 2012
Clinical Trial Update: Study shows injections into muscle safe, effective for stem cell delivery
Cell therapies are traditionally delivered through intravenous (IV) injections for systemic effect.
However, the Pluristem study found that intramuscularly administered PLX cells are safe, effective, easy to inject and provided systemic therapeutic benefits in a wide range of hematological disorders, as well as primary and secondary bone marrow failure such as that seen in radiation sickness.
The results demonstrated a significant survival and recovery rate of bone marrow and peripheral blood counts in animals pre-irradiated by high lethal doses, according to a press release issued by Pluristem. These findings indicate that the IM route of administering PLX cells stimulates the hematopoietic stem cells of the bone marrow to produce red and white blood cells as well as platelets crucial for the treatment of hematological disorders.
The study was conducted in cooperation with the Sharett Institute of Oncology at Hadassah Hospital in Jerusalem.